Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.

J Exp Clin Cancer Res · 2023 · PMC10683265 · PMID 38012687

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Intriguingly, while NR5A2 expression levels alone did not clearly separate responders from non-responders, its combination with SOX2 levels showed a highly significant separation of the two groups (Fig. 7 F).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.